OpportunityAnalyzer: Hyperparathyroidism – Opportunity Analysis and Forecasts to 2025
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Hyperparathyroidism (HPT) is a common endocrinal disorder characterised by excessive plasma levels of parathyroid hormone (PTH) stemming from overactivity of the parathyroid glands. The parathyroid glands, of which there are four, regulate physiological calcium homeostasis through a negative feedback mechanism involving PTH secretion. HPT is classified into either primary, secondary, or tertiary, and it is important to differentiate between the three as their underlying aetiology, pathology, and treatment differ. Primary HPT (PHPT), which is characterised by hypercalcemia, results from the overproduction of PTH from one or more parathyroid glands due to the formation of sporadic and/or hereditary adenomas or carcinomas on the parathyroid gland(s). Secondary HPT (SHPT) develops, in particular, due to declining kidney function and/or vitamin D deficiencies, which result in the hypersecretion of PTH in response to induced hypocalcaemia and hyperphosphatemia in this manner. Tertiary HPT is rare and occurs most commonly in patients with long-standing SHPT who develop parathyroid hyperplasia that leads to autonomous PTH production in conjunction with hypercalcemia.
Scope
Overview of HPT, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
Annualized HPT therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the HPT therapeutics market.
Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
Analysis of the current and future market competition in the global HPT therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Key Highlights
The newly launched iron-based phosphate binders, Velphoro and Auryxia, will see an increase in patient shares for the treatment secondary HPT against the cornerstone binder, sevelamer. Will these newly marketed make a significant impact on the HPT market? Which of these drugs will have the highest peak sales at the highest CAGR, and why?
The most notable candidate in the current late-stage HPT pipeline is new generation IV calcimimetic, Parsabiv (etelcalcetide), which is predicted to have a notable impact in the HPT space over this forecast period. However, there are still considerably high unmet needs within the indication. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the HPT market?
We have seen a notable increase in the HPT population in terms of diagnosed prevalent HPT cases for primary, secondary, and tertiary HPT. How will epidemiological changes impact the growth of the future market?
Shire
Shield Therapeutics
Keryx Biopharmaceuticals
Sanofi/Genzyme
Vifor Pharmaceuticals
OPKO Health, Inc.
Deltanoid Pharmaceuticals
Ardelyx
Spectrum Pharmaceuticals
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.